Company news

Entrada Therapeutics, Inc. news in 2025

Entrada Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 4, 2025

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

November 6, 2025

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

September 5, 2025

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

February 24, 2025

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

February 2, 2025

Decks in 2025